Skip to content

35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin

35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Skin Inflammation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06387212
Enrollment
20
Registered
2024-04-26
Start date
2024-04-15
Completion date
2024-05-31
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cosmetic Skin, Skin Inflammation

Keywords

whitening, pore size, skin dryness, erythema, skin hardness

Brief summary

To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.

Interventions

DRUG35 kDa hyaluronan fragment HA35 injection

First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).

Sponsors

Nakhia Impex LLC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Skin problems include but are not limited to dry skin, dark skin, and coarse pores. * Chronic skin inflammation, pigmentation, erythema, etc. * Cooperate with the experimental requirements and be able to complete the score independently。

Exclusion criteria

* Pregnant or lactating women. * Suffering from psychological or mental illness. * Life is not regular, overeating. * Hypersensitive to hyaluronic acid, and has a scar constitution.

Design outcomes

Primary

MeasureTime frameDescription
A skin dryness scale120 minutes and 960 minutesThe Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents no skin dryness, while 10 represents the worst degree of skin dryness.
A fair or smooth skin scale120 minutes and 960 minutesThe Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the worse degree of fair or smooth skin, while 10 represents the best degree of fair or smooth skin.
A skin pore size scale120 minutes and 960 minutesThe Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of skin pore size, while 10 represents the worst degree of skin pore size.
A inflammatory skin thick hardness scale120 minutes and 960 minutesThe Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of inflammatory skin thick hardness, while 10 represents the worst degree of inflammatory skin thick hardness.
An erythema color and area scale120 minutes and 960 minutesThe Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of erythema color and area, while 10 represents the worst degree of erythema color and area scale.

Secondary

MeasureTime frameDescription
Self-satisfaction evaluation1 week after the end of the treatmentOne week after the end of the treatment, a return visit was conducted to collect the overall satisfaction score of the subjects on the skin treatment. Using the questionnaire (0-10 score) to assess this outcome measure. 0 represents the most dissatisfied, while 10 represents the most satisfied.

Countries

Mongolia

Contacts

Primary ContactMizhou Hui
mizhou.hui@alumni.utoronto.ca13484005199

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026